Zelluna’s solid TCR plans

Why Zelluna plans to enter solid tumor territory with patient-sourced TCRs

Zelluna Immunotherapy A/S is using a portfolio of HLA class II-restrictive TCRs to develop autologous cell therapies that could unleash a broader immune attack on solid tumors than other TCR-based cell therapies in development.

CEO Miguel Forte said Zelluna’s products are built on a large portfolio of TCRs against antigens that are critical to tumor survival: TERT, KRAS and TGFBR2. Oslo University Hospital obtained the portfolio by

Read the full 664 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE